Doxil Stealth liposomal formulation of doxorubicin data

SEQU announced results of a Phase III trial at the American Society of Hematology meeting in Seattle, showing at least equal efficacy with ABV standard combination chemotherapy (adriamycin, bleomycin and vincristine).

Of 258 patients enrolled, 239 were evaluable; 131 received two or more cycles of Doxil, and 108 had the chemotherapy. After treatment, 48 of 120 patients on Doxil had complete or partial responses, compared to 27 of 111 patients on ABV (p<0.001). ...